Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in Argentina: a population-based, before-and-after retrospective cohort study by Arrossi, Silvina et al.
www.thelancet.com/lancetgh   Vol 7   June 2019 e772
Articles
Programmatic human papillomavirus testing in cervical 
cancer prevention in the Jujuy Demonstration Project in 
Argentina: a population-based, before-and-after 
retrospective cohort study
Silvina Arrossi, Melisa Paolino, Rosa Laudi, Juan Gago, Alicia Campanera, Oscar Marín, Cristina Falcón, Verónica Serra, Rolando Herrero, 
Laura Thouyaret
Summary
Background Human papillomavirus (HPV) testing for cervical cancer prevention was introduced in Argentina through 
the Jujuy Demonstration Project (2011–14). The programme tested women aged 30 years and older attending the 
public health system with clinician-collected HPV tests. HPV self-collection was introduced as a programmatic 
strategy in 2014. We aimed to evaluate the effectiveness of programmatic HPV testing to detect cervical intraepithelial 
neoplasia (CIN) of grade 2 or worse (CIN2+) in comparison with cytology-based screening.
Methods We did a population-based, before-and-after retrospective cohort study using data from the National Cervical 
Cancer Prevention Program for the Jujuy province in northwest Argentina. We obtained data for the cytology-based 
screening period from Jan 1, 2010, until Dec 31, 2011, and for the HPV-based screening period from Jan 1, 2012, until 
Dec 31, 2014. The primary outcome was detection of histologically diagnosed CIN2+ among women aged 30 years 
and older. To assess the outcomes in all individuals included in the study, we used multivariable logistic regression 
and propensity score matching. The reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) 
framework was used for the before-and-after analysis of programmatic dimensions.
Findings Of the 29 631 women who underwent cytology-based screening in 2010–11, CIN2+ was detected in 
236 (0·8%) individuals. Of the 49 565 women HPV tested in 2012–14 (clinician-collected tests, n=44 700; self-collection 
tests, n=4865), 693 (1·4%; 658 clinician-collected tests; 35 self-collection tests) were found to have CIN2+ after the 
first round of screening. Compared with cytology-based screening, the odds ratio of being diagnosed with a 
CIN2+ lesion was 2·34 (95% CI 2·01–2·73; p<0·0010) with clinician-collected tests, and 1·08 (0·74–1·52; p=0·68) 
when screened with self-collection tests, after controlling for age and health insurance status. Screening coverage was 
similar in both periods (52·7% vs 53·2%); improvements of programmatic indicators were observed in the HPV 
testing period in relation to laboratory centralisation, lower overscreening (6·6% vs 0·0%), higher adherance to age 
recommendations (79·3% vs 98·8%), and a decrease of inadequate samples (3·6% vs 0·2%).
Interpretation HPV testing in middle-income settings increases detection of CIN2+ lesions and allows for 
improvement of programmatic indicators. Evidence suggests that the introduction of HPV testing will accelerate the 
reduction of cervical cancer burden.
Funding Argentinian National Cancer Institute and National Council of Scientific and Technologic Research.
Copyright © 2019 The Authors. Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Cervical cancer is a major problem because of its high 
incidence and mortality in low-income and middle-
income settings.1 Developed countries have shown that 
the disease can be controlled with cytology-based 
screening2 done within organised programmes,3 but 
these programmes have been difficult to implement in 
health systems of low-income and middle-income 
countries with limited resources.4
In the past two decades, human papillomavirus 
(HPV) testing has been developed as an alternative 
screening method for cervical cancer prevention. HPV 
testing has a high sensitivity and negative predictive 
value, thus women without HPV infection are at very 
low risk of cervical cancer and do not need additional 
screening for at least 5 years.5 HPV testing accurately 
identifies women at higher risk of cervical cancer; these 
women can be followed up, diagnosed, and treated with 
a more specific protocol than if they had been tested 
with cytology-based screening.6 In addition, HPV 
testing allows for sample self-collection, which is 
effective in increasing screening uptake.7,8 These 
features have made HPV testing the preferred tool for 
cervical cancer screening. In combi nation with HPV 
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vaccination, HPV testing could accelerate elimination 
of cervical cancer.9
Cervical cancer prevention in Argentina has historically 
faced the same organisational problems as most 
countries in Latin America.10 The National Program on 
Cervical Cancer Prevention (NPCCP) was relaunched in 
2008 and in 2010 a decision was made to introduce HPV 
testing for screening.11 Jujuy, a province with high cervical 
cancer mortality (11∙8 per 100 000 in 2008–10) was chosen 
for implementation of the Jujuy Demon stration Project 
(JDP),11 a 4-year population-based study led by the 
Argentinian National Cancer Institute, done during 
2011–14 to evaluate large-scale programmatic introduction 
of HPV testing.
Descriptions of the JDP planning phase (2011), and the 
first year of screening (2012) were previously published.11 
In this Article, we present the final results of the JDP. We 
aimed to evaluate how effective HPV-based screening 
was in increasing detection of precancerous cervical 
lesions compared with cytology-based screening.
Methods
Study design and participants
The JDP was population-based and implemented by the 
NPCCP in the province of Jujuy, Argentina, to evaluate the 
introduction of HPV testing as programmatic, primary 
screening.11 The JDP involved 1 year of planning (from Jan 
1 to Dec 31, 2011) and 3 years of screening (between Jan 1, 
2012, and Dec 31, 2014). On Jan 1, 2012, all Jujuy public 
health institutions changed the primary screening method 
for cervical cancer prevention from cytology-based 
screening to HPV testing. We used a before-and-after, 
retrospective cohort study, and a pre-post design, 
combined with propensity score matching (PSM), to 
evaluate the effect of HPV testing on detection of cervical 
intraepithelial neo plasia of grade 2 or worse (CIN2+). 
Non-randomised methods are increasingly used to 
evaluate population health interventions,12 and PSM 
ensures that the average characteristics of the intervention 
and comparison groups are similar, which is deemed 
sufficient to obtain an unbiased effect.13 Such methods are 
particularly suitable when randomisation is not feasible 
and to produce data for the effect of interventions in real-
world settings. Additionally, we analysed improvement of 
key indicators related to programme organisation.
The Jujuy setting has been extensively described else-
where.8,11 The province is located in northwest Argentina 
and has around 673 000 inhabitants; 85% of the 
population live in urban areas and 32% are poor; its 
public health system includes a tertiary referral hospital, 
300 primary health-care centres, 18 diagnostic centres, 
and five treatment services. Health services are free for 
the population not covered by the social security sector 
(eg, informal workers and their families).
Cytology-based screening procedures
A situational analysis done in 200714 showed that in Jujuy, 
cervical screening coverage was low, information systems 
were unreliable, information on follow-up and treatment 
was missing, and providers had low adherence to 
programmatic norms and recommendations. Cytology 
results were read in six laboratories, which processed in 
total around 22 000 annual samples without quality 
controls.
Before 2012, cytology-based screening was recom-
mended in Argentina for women aged 25 years and older, 
every 3 years after two consecutive negative Papanicolaou 
(Pap) smear tests, but annual screening was common 
Research in context
Evidence before this study
The initial search to define the study protocol covered PubMed 
between Jan 1, 2002, and Dec 31, 2010. The search was extended 
to Jun 30, 2018, when writing the manuscript. Relevant 
publications with the key terms “cervical cancer”, “HPV testing”, 
“cervical cancer screening”, “clinical trials”, and “self-collection” 
were reviewed for quality and relevance. Only studies written in 
English or Spanish were considered. We found that much of the 
evidence about the effect of human papillomavirus (HPV) testing 
comes from randomised controlled trials, and to our knowledge 
no study has assessed how HPV testing has performed in real-
world programmatic conditions of middle-income settings 
compared with cytology-based screening.
Added value of this study
This study analysed results from the Jujuy Demonstration 
Project, which ran from 2012–14, and was one of the 
first population-based HPV testing projects done in a 
middle-income setting.
Implications of all the available evidence
Results from the Jujuy Demonstration Project study are very 
important for similar settings implementing or considering 
implementing HPV testing. The study showed that, compared 
with cytology, programmatic HPV testing doubled detection 
of cervical intraepithelial neoplasia of grade 2 or worse (CIN2+) 
lesions, confirming available evidence from randomised 
controlled trials. In addition, introduction of HPV testing can 
facilitate the programme and health service reorganisation 
needed to improve programme indicators. Therefore, 
although the positive predictive value was lower and the 
colposcopy referral frequency was higher in the HPV testing 
group compared with the cytology group, adherence to 
colposcopy was similar in both groups. Further analysis 
should provide supportive evidence showing that the 
increased detection of CIN2+ lesions in this first round of 
screening represents early detection and not overdiagnosis, 
as shown by studies with longer follow-up.
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practice. Colposcopy, and biopsy if needed, was recom-
mended for women with atypical squamous cells in 
whom high-grade or worse lesions could not be excluded 
(atypical squamous cells for which high-grade squamous 
intraepithelial lesions cannot be ruled out or worse 
[ASC-H+], high-grade squamous intraepithelial lesion, 
or cancer). Women with atypical squamous cells of 
undetermined significance (ASCUS) or low-grade squa-
mous intra epithelial lesions (LSIL) were recommended 
for re-screening in 6 or 12 months.
HPV-based screening procedures
In 2012, the JDP introduced HPV testing (Hybrid 
Capture 2; Germantown, MD, USA) for primary 
screening11 of women aged 30 years and older, irrespective 
of previous screening history. JDP protocols have been 
described elsewhere.11 Briefly, women who were 
HPV-positive were triaged with cytology-based screening. 
Individuals whose samples were classified as ASCUS or 
worse (ASCUS+) were referred to colposcopy and biopsy 
if needed. Women with histologically confirmed CIN2+ 
were referred for treatment. Women who were HPV 
negative were recommended re-screening in 5 years. 
HPV testing and cytology triage were collected simul-
taneously, but cytology was read only if the individual 
was HPV-positive. Women who were HPV-positive but 
had normal cytology were recommended re-screening in 
18 months. Women younger than 30 years continued to 
undergo cytology-based screening.
The Jujuy primary health-care system employs more 
than 700 full-time community health workers, who visit 
around 110 000 households (70% of total provincial 
households) twice each year for health-related tasks 
including promotion of HPV testing.11 On the basis of the 
EMA study,8 which showed a four-times increase in 
screening uptake due to self-collection, the strategy of self-
collection offered by community health workers during 
home visits was scaled up in 2014.15 The strategy targeted 
women aged 30 years and older from households visited 
by community health workers, who had not been screened 
in the previous 5 years, and with public health coverage. 
Women who were HPV-positive who used self-collection 
tests had to attend health centres for cytology triage. 
At present, self-collection is in use in four Argentinian 
provinces.
Data sources
Since 2010 in Jujuy, any instance of screening, diagnosis, 
or treatment using public health services has been 
registered in the national screening information system 
(SITAM).16 The HPV laboratory used SITAM to manage 
samples at entry; the samples of individuals that did not 
comply with the recommended age range or screening 
frequency were not processed. Women were informed 
about why their test was not analysed and were reminded 
of the date of their next HPV test. The protocol was 
approved by the CEMIC Institutional Review Board 
(protocol number 1186). De-identification of the data-
bases protected the identity of participants. Verbal 
informed consent was obtained according to the national 
regulations for standard medical practices (Patient’s 
Rights Act 26.529). Specific consent was not required for 
statistical analysis of aggregated de-identified data.
We extracted data from SITAM for the purposes of this 
analysis.16 Colposcopies, biopsies, and treatments not 
registered in SITAM were considered lost to follow-up, 
including those done in private services without con-
firmation by the provincial programme. Information on 
health insurance was obtained from the National 
Database on Health Insurance.
Outcomes
We compared key programmatic indicators using 
the reach, effectiveness, adoption, implementation, 
and maintenance (RE-AIM) framework,17 specifically 
developed to expand assessment of interventions beyond 
efficacy to multiple criteria. This analysis might better 
Figure 1: Screened women by year, Jujuy 2010–14
70% 69% 63% 63% 63%
























Age (years) 42·9 (10·3) 43·1 (10·4)
30–34 7851 (26·5%) 12 582 (25·4%)
35–44 10 478 (35·4%) 17 923 (36·2%)
45–54 6624 (22·4%) 10 775 (21·7%)
55–64 3711 (12·5%) 6486 (13·1%)
65 and older 967 (3·3%) 1799 (3·6%)
Health insurance
Private or social 8783 (29·6%) 17 902 (36·1%)
Public 20 848 (70·4%) 31 663 (63·9%)
Target population†
No 9052 (30·5%) 18 456 (37·2%)
Yes 20 579 (69·5%) 31 109 (62·8%)
Data are n (%) or mean (SD). HPV=human papillomavirus. *Clinician-collected and 
self-collected tests combined. †Yes=women aged 30–64 years with public health 
insurance; No=women aged 30–64 years with private or social health insurance 
and those aged 65 years or older with any health insurance.
Table 1: Sociodemographic characteristics of screened women, 
Jujuy 2010–14
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identify the translatability and public health effect of 
health promotion interventions, balancing the emphasis 
on internal and external validity.17,18 The RE-AIM frame-
work is particularly appropriate for assessing the public 
health effect of the intervention as a function of the five 
factors that comprise the RE-AIM acronym, all of which 
are considered necessary for success.17
In assessing reach (defined as the proportion of 
individuals who receive or are affected by a policy or 
programme17), our goal was to evaluate how HPV testing 
influenced the capacity of the provincial programme to 
achieve high screening coverage. We defined coverage as 
the proportion of women aged 30–64 years with public 
health insurance screened at least once in each period of 
the estimated number of target women (2-year cytology 
period n=39 000; 3-year HPV period n=58 500, according 
to the National Census 2010). For the HPV testing period, 
we measured coverage including women that had 
clinician-collected tests and coverage including both 
women who had a clinician-collected test and those who 
submitted a self-collected test.
Our primary effectiveness outcome was histologically 
confirmed CIN2+ detection among women aged 30 years 
or older screened between Jan 1, 2010, and Dec 31, 2014. 
When referring to effectiveness, we followed the 
definition of Rabin and Brownson,19 which refers to the 
effect of an intervention that has shown efficacy when it 
is delivered under real-world conditions. Detection was 
calculated as follows: (1) proportion of women who 
underwent cytology-based screening who had CIN2+ 
detected of the total number of women who under went 







Total screened aged ≥30 years 44 700 4865 29 631
Test-positive 6111 (13·7%) 633 (13·0%) 1178 (4·0%)
Detection by screening
CIN2+ 552 (1·23%) 35 (0·72%) 236 (0·80%)
CIN2 91 (0·20%) 7 (0·14%) 55 (0·19%)
CIN3* 405 (0·91%) 21 (0·43%) 158 (0·53%)
CA 56 (0·13%) 7 (0·14%) 23 (0·08%)
CIN2+ detection rate 
(per 1000 screened women)
12·3 7·2 8·0
CIN3+ detection rate 
(per 1000 screened women)
10·3 5·7 6·1
Detection by follow-up of HPV-positive women with negative cytology
CIN2+ 106 (0·24%) 0 NA
CIN2 21 (0·05%) 0 NA
CIN3* 81 (0·18%) 0 NA
CA 4 (0·01%) 0 NA
CIN2+ detection rate 
(per 1000 screened women)
2·4 0·0 NA
CIN3+ detection rate 
(per 1000 screened women)
1·9 0·0 NA
Overall CIN2+ detection rate 
(per 1000 screened women)
14·7 7·2 8·0
Overall CIN3+ detection rate 
(per 1000 screened women)
12·2 5·7 6·1
Referral to colposcopy 1663 (3·7%) 150 (3·1%) 403 (1·4%)
Overall positive predictive value 10·8% 5·5% 20·0%
Data are n or n (%), unless otherwise specified. HPV=human papillomavirus. CIN=cervical intraepithelial neoplasia. 
CA=carcinoma. NA=not applicable. *CIN3 includes adenocarcinoma in situ.
Table 2: Screening performance indicators by type of tests
Figure 2: Follow-up of women with ASC-H or worse lesions detected by cytology, Jujuy 2010–11
ASC-H+=atypical squamous cells for which high-grade squamous intraepithelial lesions cannot be ruled out or worse. ASCUS=atypical squamous cells of 
undetermined significance. CIN=cervical intraepithelial neoplasia. LSIL=low-grade squamous intraepithelial lesions.
29 631 total cytology samples
28 453 negative cytology samples 775 ASCUS or LSIL samples
100 women with ASC-H+ at 
follow-up
135 women without 
colposcopy
368 women with 
colposcopy or biopsy
403 ASC-H+ samples
132 women with normal biopsy
 or CIN1 lesions
236 women with CIN2+ 
lesions
46 women without 
treatment
190 women with 
treatment
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who underwent HPV screening (including both clinician-
collected and self-collected tests) who had CIN2+ detected 
of the total number of women who underwent HPV 
screening. CIN2+ lesions detected by HPV testing also 
included those detected at 18-month follow-up in women 
who were HPV-positive but had normal cytology at the 
original screening. The proportion of women who had 
CIN3+ lesions detected was also calculated. The positive 
predictive value for HPV testing was calculated at both 
baseline and follow-up at 18 months. Histological 
confirmation was considered the gold standard. We 
calculated odds ratios (ORs) and 95% CIs to assess the 
CIN2+ detection effectiveness of HPV compared 
with cytology, and calculated CIN2+ detection rate (per 
1000 screened women) through a descriptive before-and-
after analysis using two periods: (1) the 2-year cytology-
based screening period preceding the introduction of 
HPV testing, 2010–11; and (2) the HPV period, 2012–14.
Adoption refers to the intention to use an innovation or 
evidence-based practice.20 For each period we measured 
the following: the proportion of primary health-care 
centres that provided the screening method of the total 
number of primary health-care centres; the proportion of 
women screened within the recommended age range 
(aged 25 years or older for cytology-based screening, and 
30 years or older for HPV screening) of the total number 
of women who were screened; and the proportion of 
women who were over-screened of the total number of 
Figure 3: Follow-up of women who were HPV-positive who had clinician-collected tests, Jujuy 2012–14
CIN=cervical intraepithelial neoplasia. HPV=human papillomavirus. PHS=public health system.
44 700 women had a clinician-collected test
92 women had unsatisfactory cytology
109  women were without cytology
4247 women had normal 
cytology
1663 women had triage
1657 women had 
abnormal cytology
6 women underwent 
coloscopy triage
2509 women had a 
secondary HPV test
423 women without 
coloscopy because of loss 
to follow-up
6111 women were HPV-positive
1240 women with coloscopy
56 women were 
without 
available results
289 women had 
normal results


















473 women with 
treatment
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women who were screened. Over-screening was defined 
as screening done more than once per year for cytology-
based screening; and more than once in the 3-year period 
for HPV screening.
Implementation refers to the extent to which a 
programme is delivered as intended.20 In each period, we 
measured four outcomes. The first was laboratory 
organisation—ie, the number of laboratories processing 
the primary screening test. The second was changes in 
sample quality—ie, the proportion of inadequate cytology 
samples of the total number of cytology samples 
(2010–11); and the proportion of HPV samples discarded 
at the laboratory of the total number of HPV samples 
(2012–14). We additionally measured the proportion of 
inadequate cytology-based triage samples of the total 
number of cytology triage samples. The third was 
completion of follow-up, which was split into four parts: 
(1) the proportion of women with a positive Pap test 
result who had a colposcopy of the total number of 
women with a positive test result (ie, for the cytology 
Figure 4: Follow-up of women who were HPV-positive who did self-collected tests, Jujuy 2014
CIN=cervical intraepithelial neoplasia.
16 women had a 
colposcopy
633 women were HPV-positive
4865 women used self-collection tests















36 women were 
negative for 















6 women had 
abnormal 
samples














31 women had 
CIN2+ 
lesions





4 women had 
CIN2+ 
lesions













www.thelancet.com/lancetgh   Vol 7   June 2019 e778
period, the proportion of women with ASC-H+ cytology 
that complied with colposcopy of the total number of 
women who had ASC-H+; for the HPV period, the 
proportion of HPV-positive women with ASCUS+ who 
had a colposcopy of the total number of HPV-positive 
women with ASCUS+); (2) the proportion of HPV-
positive women with normal cytology who complied with 
follow-up at 18 months (HPV period) and the proportion 
of women with ASCUS or LSIL who complied with 
follow-up at 12 months (cytology period); and (3) for the 
HPV period we also measured the proportion of women 
with self-collection HPV-positive tests who had triage 
(cytology or colposcopy). The fourth was the proportion 
of women who received treatment of the total number of 
women with CIN2+ lesions.
Maintenance is the extent to which a programme or 
policy becomes institutionalised or part of the routine 
organisation practices and policies.18 We presented the 
number of new women tested for HPV (both with 
clinician-collected and self-collection tests) in 2015–17, 
after the JDP was finalised.
Statistical analysis
Mean age as a continuous variable was compared 
between the cytology-based period and HPV-based period 
using the Wilcoxon rank-sum test. Multivariable logistic 
regression was used to measure the magnitude of the 
effect of HPV testing on CIN2+ detection compared with 
cytology-based screening, after adjusting for age and 
health insurance status.
To account for potential selection into the intervention 
group and minimise bias, we developed a second model 
using PSM. Included variables were age (in years) and 
health insurance status. Functionality of PSM requires 
datasets with no missing values. To handle missing data, 
we used average imputation for age (six missing cases) 
and random imputation for health insurance (13 missing 
cases). The matching algorithm chosen was the nearest 
neighbour algorithm, using a caliper value of 0∙1 SD.
We used R statistical software (version 3.5.0) for all 
analysis, and Matchit R Package (version 3.0.2) for the 
PSM.
Role of the funding source
The funder had no role in study design, data collection, 
analysis, or writing of the report. The corresponding 
author had full access to all data in the study and had 
final responsibility for the decision to submit for 
publication.
Results
Between Jan 1, 2010, and Dec 31, 2014, 79 196 women 
aged 30 years and older were screened; 29 631 women 
underwent cytology-based screening in 2010–11, and 
49 565 women were tested for HPV in 2012–14. All 
women were included in the analysis. Most cytology-
based screened women were screened in 2011 (17 185 
[58·8%] of 29 631) and most HPV tested women were 
screened in 2012 (22 515 [45·4%] of 49 565); figure 1). 
Among the 49 565 women who were tested for HPV, 
44 700 (90·2%) had clinician-collected tests and 
4865 (9·8%) used self-collection tests. In 2014, when self-
collection screening was introduced, the method 
represented 38·1% (4865 of 12 779) of all screening tests 
in the study sample.
Compared with women who underwent cytology-based 
screening, a lower proportion of women who were HPV 
tested (both clinician-collected and self-collection tests) 
had public health insurance and were from the target 
population (table 1). Although the mean age of the 
two groups was numerically similar, according to the 
Wilcoxon rank-sum test, individuals who underwent 
cytology-based screening were significantly younger than 
those who underwent HPV screening (42·9 years vs 
43·1 years; p=0∙013). Among the 4865 women who used 
self-collection tests, 3520 (72·4%) had public health 
insurance, and 3265 (67·1%) were from the target 
population.
Figures 2–4 show the follow-up of screened women for 
method of screening. Screening performance indicators 
by type of test are shown in table 2. CIN2+ was detected 
in 236 (0·8%) of 29 631 women who had undergone 
cytology-based screening, (figure 2) and the positive 
predictive value was 20·0%. CIN2+ was detected in 
552 (1·23%) of 44 700 women who had undergone 
clinician-collected tests in the first round of screening. 
2509 (59·1%) of the 4247 women who were HPV-positive 
with normal cytology were re-screened (figure 3); CIN2+ 
was detected in 106 (0·24%) individuals in this group. 
Overall, 658 CIN2+ lesions were detected through 
clinician-collected tests, and the positive predictive value 
was 10·8%. 35 CIN2+ lesions were identified among 
Pre-propensity score matching Post-propensity score matching
OR (95% CI) p value OR (95% CI) p value
Screening method
Cytology 1 (ref) ·· 1 (ref) ··
Self-collected HPV test 1·08 (0·74–1·52) 0·68 1·15 (0·73–1·72) 0·52
Clinician-collected HPV test 2·34 (2·01–2·73) <0·0001 2·31 (1·95–2·74) <0·0001
Age, years
30–44 1 (ref) ·· 1 (ref) ··
35–44 0·89 (0·75–1·05) 0·15 0·89 (0·76–1·05) 0·18
45–54 0·72 (0·59–0·88) <0·0001 0·74 (0·58–0·93) 0·011
55–64 0·96 (0·77–1·19) 0·69 1·06 (0·72–1·51) 0·75
≥65 1·57 (1·13–2·14) 0·0057 2·34 (1·35–3·81) 0·0012
Health insurance
Private 1 (ref) ·· 1 (ref) ··






CIN=cervical intraepithelial neoplasia. OR=odds ratio. HPV=human papillomavirus.
Table 3: Logistic regression of CIN+ detection frequency with and without propensity score matching
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women using self-collection tests (figure 4), and the 
positive predictive value was 5·5%. Of the 257 women 
who used self-collection tests who were HPV-positive 
with normal cytology, 41 (16%) were re-screened, but no 
CIN2+ lesions were identified in this group. Overall, 
693 (1·4%) of 49 565 women who underwent HPV testing 
(including both clinician-collected and self-collection 
tests) had CIN2+ lesions detected. The proportion of 
individuals who were referred for colposcopy was 
403 (1·4%) of 29 631 for cytology-based screening 
(figure 2), 1663 (3·7%) of 44 700 for clinician-collected 
tests, and 150 (3·1%) of 4865 for self-collection tests.
Results from the multivariate logistic regression and 
PSM are shown in table 3. The odds of being diagnosed 
with a CIN2+ lesion were higher when using clinician-
collected testing than with cytology-based screening, 
after controlling for age and health insurance (OR 2·34; 
95% CI 2·01–2·73; p<0·0001). After PSM, the odds of a 
CIN2+ result using HPV testing were similar to before 
PSM. The odds of being diagnosed with a CIN2+ lesion 
were similar for women who used self-collection tests 
and those using cytology-based screening, both before 
and after PSM (table 3). Analysis including only 
individuals with CIN3+ lesions did not change results 
(clinician-collected HPV testing vs cytology, OR 2∙54, 
95% CI 2·14–3·03; p<0·0001; self-collection HPV testing 
vs cytology, OR 1·20, 95% CI 0·8–1·75; p=0∙34). We ran 
additional models evaluating the possible inter action 
between method of screening and the variables of age and 
health insurance status. In these models, the interaction 
terms were not statistically significant, whereas all other 
variables remained statistically significant—as in the 
model without interaction.
Key programmatic indicators assessed by before-and-
after analysis using the RE-AIM framework are shown in 
table 4. Regarding reach, estimated coverage was 
52·7% for the cytology period (20 579 of 39 000), and 
47·5% for the HPV period (27 844 of 58 500) when only 
women who had clinician-collected tests were considered, 
and 53·2% if both clinician-collected and self-collection 
tested women are included (31 109 of 58 500).
100% of health-care centres adopted the screening 
method in each period. The percentage of screened 
women within the recommended age range was higher 
in the HPV period: 98·8% (aged 30 years and older) 
versus 79·3% in the cytology period (aged 25 years and 
older). Over-screening was 0·0% in the HPV period 
and 6·6% in the cytology period.
The implementation of the programme involved 
six laboratories processing cytology-based screening 
tests in 2009; this number was reduced to three by 2011. 
In 2012, a central HPV-cytohistology laboratory was 
created. The percentage of inadequate samples of the 
primary screening test was reduced from 3·6% (cytology 
period) to 0·2%. The percentage of women with ASC-H+ 
with colposcopy was similar among women screened 
Cytology-based period HPV test overall Clinician-collected test Self-collected test
Reach
Women aged 30–64 years with public health insurance who were screened at 
least once in each period (%)
20 579/39 000 (52·7%) 31 109/58 500 (53·2%)* 27 844/58 500 (47·5%) 3225/58 500 (5·7%)*
Effectiveness
CIN2+ detection rate in women aged ≥30 years (per 1000 screened women) 8·0 14·7 12·4 7·2
Odds ratio (95% CI) vs cytology 1 (ref) ·· 2·34 (2·01–2·73) 1·08 (0·74–1·52)
Adoption
Health-care centres that provided screening method in each study period (%) 300/300 (100%) 300/300 (100%) 100% NA
Women of the recommended age screened in each study period (%) 38 043/47 927 (79·3%) 49 565/50 147 (98·8%) 44 700 4865
Women who were over-screened in each period 2500/38 046 (6·6%) 0/49 565 0 0
Implementation
Laboratories processing screening tests for women aged ≥30 years (n) 6† 1 1 1
Inadequate primary test samples (%) 2045/56 709 (3·6%) 121/49 686 (0·2%) 56 65
Inadequate cytology-based triage (%) NA 156/7052 (2·2%) NA NA
Follow-up: triage-positive women who had a colposcopy (%) 380/526 (72·2%) NA 1240/1663 (74·6%) 105/150 (70·0%)
Follow-up: women with CIN2+ who had registered treatment (%) 200/249 (80·3%) NA 463/552 (83·9%) 28/35 (80·0%)
Follow-up: women with ASCUS or LSIL who were followed up at 12 months 
(cytology-based period) and women who were HPV-positive with normal 
cytology who were followed up at 18 months (HPV-based period, %)
345/775 (44·0%) 1169/2509 (46·6%) 1169 NA
Follow-up: women with HPV-positive self-collected tests who were triaged 
(cytology or colposcopy, %)
NA 491/633 (77·6%) NA 491
Maintenance (2 years after study end)
HPV-tested women, 2015–17 (n) NA 30 975 19 795 11 180
CIN2+=cervical intraepithelial neoplasia of grade 2 or worse. NA=not applicable. ASCUS=atypical squamous cells of undetermined significance. LSIL=low-grade squamous intraepithelial lesions. HPV=human 
papillomavirus. *Self-collected testing was introduced in 2014, so its contribution to reach is based on 1 year only. †In 2010; the number of cytology laboratories was reduced to three in 2012.
Table 4: Reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) measurement
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in the HPV period (clinician-collected 74·6% vs 
self-collection 70·0%) to those screened in the cytology-
based period (72·2%). In total, 491 (77·6%) women with 
HPV-positive self-collection tests were triaged. The 
percentage of treated CIN2+ lesions was similar in all 
three groups, around 80%. The percentage of re-
screening of women who were HPV-positive with normal 
cytology at 18 months (46·6%) was similar to the 
percentage of re-screening of women with ASCUS or 
LSIL at 12 months in the cytology-based period (44·0%).
Regarding effectiveness, CIN2+ detection rates were 
12·3 per 1000 screened women for clinician-collected 
tests, 7·2 per 1000 screened women for self-collected tests, 
and 8·0 per 1000 screened women for cytology tests. 
When compared with cytology, clinician-collected testing 
detected more cases of CIN2+, whereas no significant 
differences were observed between self-collected tests and 
cytology tests.
For maintenance, during 2015–17, 30 975 women who 
were new to the screening programme were HPV-tested: 
19 795 (63·9%) with clinician-collected tests and 
11 180 (36·1%) with self-collection tests. The number of 
women who were new to the screening programme who 
were HPV-tested was similar in each year (data not 
shown).
Discussion
To our knowledge, these are the first systematic results of 
HPV testing introduced as a population-based public 
health policy for cervical cancer screening in a middle-
income setting. Our findings advance the existing public 
health literature by showing that effective screening with 
HPV testing in real-world programmes of middle-
income settings is feasible. This is particularly important 
given the global call for cervical cancer elimination 
launched by WHO.21
Clinician-collected HPV testing significantly increased 
detection of CIN2+ lesions when compared with cytology-
based screening, supporting the results from the first year 
of the JDP.11 Randomised controlled trials have also 
showed an increase in CIN2+ detection with HPV testing 
compared with cytology-based tests in trials done in high-
income settings.22–24 In our study, detection of CIN2+ was 
based on pathological diagnoses done within the Jujuy 
public health system. Therefore, our results showed what 
can realistically be achieved by HPV testing in middle- 
income settings. The JDP implied improvements in 
programmatic organisation, which might be a possible 
explanation for the increased CIN2+ detection frequency. 
A refresher course was provided to colposcopists in 
provincial public health centres, probably increasing their 
diagnostic accuracy. Also, the fact that women referred for 
colposcopy were all HPV-positive might have increased 
the colposcopist’s alertness. Laboratory centralisation and 
cytologists knowing that slides were from women who 
were HPV-positive might have improved cytological 
diagnosis.25 Cytology-based screening has been a main 
factor in explaining the lack of effectiveness of screening 
in low-income and middle-income countries.4 Problems 
are related to its low to moderate sensitivity, but also to 
organisational problems faced by health systems due to 
the complexity of cytology-based screening. An analysis of 
the programmatic effect of introducing HPV testing 
showed that HPV testing is an opportunity to change 
inefficient components of screening programmes.26 
Therefore, HPV testing has been recommended as a 
strategy to simplify and improve screening organisation.27
Some concerns exist about the increased CIN2+ 
detection frequency representing overdiagnosis of 
lesions that would not have progressed to invasive 
cancer.28 Although our study did not evaluate this issue, 
evidence has shown that the increased sensitivity of HPV 
testing for CIN2+ reflects earlier detection rather than 
overdiagnosis.28–29 Sasieni30 has pointed out that because 
HPV testing prevents substantially more cancers than 
cytology-based screening, even if some of the CIN2+ 
lesions will not progress, we should accept a small 
increase in the numbers of women treated for CIN to 
achieve that benefit. In the JDP, only women with 
histologically confirmed CIN2+ lesions were treated.
Over-referral to colposcopy has been pointed out as a 
major problem in HPV testing, which is related to the 
test’s low specificity.31 Over-referral also depends on the 
screening protocol, and is higher when all women who 
are HPV-positive are referred for colposcopy.32 In the 
JDP, only women who were HPV-positive with abnormal 
cytology were referred for colposcopy. It has also been 
shown that, with appropriate protocols, increased referral 
is limited to the first round of screening with HPV 
testing28 and that in successive rounds referral will be 
lower than in cytology-based screening. In Argentina, 
the reco mmendation of the main scientific societies33 
for cytology-based screening is referral to colposcopy 
after ASCUS+ diagnosis, a widespread practice among 
gynaecologists from all over the country despite 
programmatic recommendations.34 Therefore, the HPV 
testing protocol probably resulted in a more efficient use 
of colposcopy given that it was provided to women who 
were high risk (ie, individuals who were HPV-positive 
and had abnormal cytology). However, close monitoring 
of the implications for colposcopy services should be 
done in each setting before introducing HPV testing. 
The low specificity of HPV testing can also have a 
negative psychosocial impact in women.31 To reduce this 
effect, the JDP communication strategy emphasised the 
fact that HPV infection is a common and prevalent 
condition, and that HPV positivity did not mean cancer.35
Despite the increase in colposcopy referral, completion 
of colposcopy was higher in the clinician-collected testing 
group (75%) than in the cytology group (72%). Studies 
done in Latin America and the Caribbean have reported 
a wide range of adherence to colposcopy after abnormal 
cytology (21–99%).36,37 In Jujuy, a patient navigation 
programme provides support to women who are 
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HPV-positive and have abnormal cytology to facilitate 
their access to follow-up or treatment.37 Also, the province 
had capacity to respond to the increase in colposcopies 
resulting from the HPV testing strategy. However, 
adherence to colposcopy was lower in women who used 
self-collection tests. In addition, only 69% of those 
women had cytology triage compared with 98% of 
women who underwent clinician-collected tests. This 
result was mainly because clinician-collected tests and 
cytology-based tests were taken simultaneously, whereas 
women who used self-collection tests needed to undergo 
a subsequent visit to a health centre for triage. This 
additional visit is a major drawback of self-collection 
tests. Low compliance to follow-up among women with 
positive self-collection tests has been reported for other 
settings.38 Several studies are evaluating triage alter-
natives (eg, methylation, genotyping, among others) to 
reduce the number of steps in the diagnostic process.25 
Meanwhile, strategies that facilitate women’s access to 
triage need to be devised.
Low coverage is a major problem in middle-income 
settings. Our results showed no effect in coverage after 
introduction of HPV testing, probably because health 
authorities had already given high priority to increasing 
coverage in the period preceding HPV testing. However, 
clinician-collected screening has coverage limitations 
due to socioeconomic, cultural, and institutional 
barriers faced by women, and the high number of 
women who were screened in the first year of the JDP 
could not be replicated in following years. Self-collection 
tests offered by community health workers during 
home visits were introduced in 2014 to counteract this 
coverage decrease.15 In 2014, self-collection represented 
38% of total HPV testing and, if we consider the whole 
JDP, 10% of screening in the target population was 
achieved through self-collection. Among women who 
used self-collection tests, the CIN2+ detection frequency 
was 7·2 per 1000 screened women, lower than detection 
by clinician-collected tests. This figure is lower than that 
reported in studies in other countries39 and in the EMA 
study in Argentina.8 This decreased detection seen with 
self-collection tests is probably due to loss to triage but 
also to the significantly lower sensitivity of Hybrid 
Capture 2 on self-collection samples than with clinician-
collected samples.39 When compared with cytology-
based tests, self-collection tests did not show significant 
differences in CIN2+ detection, but this might be due to 
the low amount of self-collection tests included in the 
analysis. A study of programmatic self-collection in 
Jujuy showed that self-collection testing allowed for the 
increase in screening uptake among socially vulnerable 
women who were under-screened, a group with 
the highest risk of cervical cancer.15 Thus, the possibility 
of self-collection testing constituted a substantial 
advantage of HPV testing for the increase of coverage, 
despite CIN2+ detection being hampered by the loss 
to triage.
The JDP was done over a 3-year period. Given that in 
Argentina the recommended screening frequency for 
women who are HPV-negative is every 5 years, coverage 
targets might be attainable if the 5-year interval is used 
instead. An estimation of coverage if women HPV-tested 
in 2015–16 were included supports this. We estimated 
coverage including HPV tested women during 2015–16 
and results showed that 75% of the target population was 
screened in the 5-year period.
HPV testing has introduced a subgroup of women who 
are HPV-positive but have normal cytology. In our study, 
59% of these women were re-screened and, among them, 
less than half had persistent HPV infection at repeated 
testing. Follow-up of these women contributed an 
additional 15% of CIN2+ lesions detected overall, con-
firming the importance of this step of the algorithm. Low 
compliance with repeated testing was common in several 
studies.40 Adherence to follow-up depends on several 
factors, including type of recommended follow-up. A 
review of studies showed that around 90% of women 
complied with follow-up if they were immediately 
referred for colposcopy based on their screening tests 
alone.40 Follow-up was considerably lower when women 
who were HPV-positive were recommended to first 
undergo repeated testing 6–18 months after initial 
screening than women who were immediately referred 
for colposcopy.40 However, colposcopy for women who are 
HPV-positive and have normal cytology is not recom-
mended due to its complexity and cost, and the low 
sensitivity and specificity of the method.27,41 As most HPV 
infections disappear in 12–24 months,42 re-screening of 
these women at 18 months seems a reasonable strategy to 
reduce costs and avoid overtreatment. However, time 
elapsed between screening and retesting can constitute a 
barrier to rescreening adherence.
Our results showed that introduction of HPV testing 
allowed for reorganisation of the laboratory network. 
A key issue was the installation of the HPV-testing 
laboratory as part of central cytology-pathology-HPV-
testing. Cytology laboratories in middle-income settings 
face problems linked to quality control, decentralisation 
in small laboratories, and lack of technical staff, among 
others.43 HPV testing not only changed the function of 
cytology from screening to triage, but also facilitated 
laboratory centralisation by prompting the political 
decisions needed for reorganisation of human resources 
and the referral network. These changes would have 
probably been more difficult to implement if HPV testing 
had not been introduced.
Low adherence to cytology screening guidelines has 
been widely reported.9 In an HPV screening scenario, 
this low adherence to guidelines might result in 
ineffective use of resources, inappropriate screening of 
young women, overtreating lesions that normally clear 
within a few months,6 and potential harm such as adverse 
pregnancy outcomes.44 Over-screening was eliminated 
with HPV testing, and screening done on individuals 
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outside of the recommended age range was greatly 
reduced. HPV protocols were established through a 
participatory process with the main scientific societies 
of Argentina.11 Also, samples not complying with the 
recommended age range or frequency for screening were 
not processed, which has discouraged screening outside 
of national recommendations.
Analysis of maintenance showed that HPV testing 
continued after the JDP and became the standard primary 
screening method. Integrating activities into existing 
health systems has been identified in the literature as an 
important factor for successful scale-up.45 On the basis of 
results from the JDP, a decision was made by the national 
Ministry of Health to expand HPV testing. At present, 
eight of 24 provinces have primary HPV testing, and 
six other provinces will introduce it by 2020.
A key limitation of the study concerned cytology-based 
screening data only being available for the 2 years before 
introduction of HPV testing. A longer medical history 
from cytology-based screening records might have 
changed results. Overscreening might be underestimated, 
as the analysed period was shorter than the recommended 
intervals. Also, our study might be affected by selection 
bias because PSM controls for measured confounders, 
but, unlike randomisation, does not control for 
unmeasured or unknown confounders. Finally, our study 
design did not allow the measurement of detection of 
CIN2+ in subsequent rounds of screening, and we were 
not able to measure the effect of HPV testing on cervical 
cancer incidence.
In summary, HPV testing resulted in increased 
detection of CIN2+ lesions in a middle-income setting. 
This increased detection was achieved in the context of 
programme reorganisation that included laboratory and 
referral network reorganisation, use of self-collection to 
increase coverage, and development of mechanisms to 
assure adherence to guidelines. Our study provides key, 
real-world evidence for low-income and middle-income 
countries to incorporate HPV testing.
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